CA3167318A1 - Polypeptides, compositions, and their use to treat or limit development of an infection - Google Patents

Polypeptides, compositions, and their use to treat or limit development of an infection Download PDF

Info

Publication number
CA3167318A1
CA3167318A1 CA3167318A CA3167318A CA3167318A1 CA 3167318 A1 CA3167318 A1 CA 3167318A1 CA 3167318 A CA3167318 A CA 3167318A CA 3167318 A CA3167318 A CA 3167318A CA 3167318 A1 CA3167318 A1 CA 3167318A1
Authority
CA
Canada
Prior art keywords
amino acid
acid sequence
seq
nanoparticle
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3167318A
Other languages
English (en)
French (fr)
Inventor
Neil P. King
David VEESLER
Carl WALKEY
Alexandra C. WALLS
Jing Yang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WASHINGTON, University of
Original Assignee
WASHINGTON, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WASHINGTON, University of filed Critical WASHINGTON, University of
Publication of CA3167318A1 publication Critical patent/CA3167318A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CA3167318A 2020-02-14 2021-02-12 Polypeptides, compositions, and their use to treat or limit development of an infection Pending CA3167318A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062977036P 2020-02-14 2020-02-14
US62/977,036 2020-02-14
US202063046159P 2020-06-30 2020-06-30
US63/046,159 2020-06-30
US202063064235P 2020-08-11 2020-08-11
US63/064,235 2020-08-11
PCT/US2021/017799 WO2021163438A1 (en) 2020-02-14 2021-02-12 Polypeptides, compositions, and their use to treat or limit development of an infection

Publications (1)

Publication Number Publication Date
CA3167318A1 true CA3167318A1 (en) 2021-08-19

Family

ID=74873805

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3167318A Pending CA3167318A1 (en) 2020-02-14 2021-02-12 Polypeptides, compositions, and their use to treat or limit development of an infection

Country Status (13)

Country Link
US (1) US20240277831A1 (cg-RX-API-DMAC7.html)
EP (1) EP4103230A1 (cg-RX-API-DMAC7.html)
JP (1) JP7897796B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220142472A (cg-RX-API-DMAC7.html)
CN (1) CN116096404A (cg-RX-API-DMAC7.html)
AU (1) AU2021221139A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016220A2 (cg-RX-API-DMAC7.html)
CA (1) CA3167318A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022011467A2 (cg-RX-API-DMAC7.html)
MX (1) MX2022009860A (cg-RX-API-DMAC7.html)
PE (1) PE20230301A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552099A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021163438A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US11192940B2 (en) 2020-04-10 2021-12-07 Adagio Therapeutics, Inc. Compounds specific to coronavirus S protein and uses thereof
US20220016268A1 (en) * 2020-07-17 2022-01-20 Tonix Pharmaceuticals Holding Corp. Skin-based testing for detection of cell-mediated immune responses to sars-cov-2
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
US20220324918A1 (en) * 2021-03-30 2022-10-13 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE ECTODOMAIN POLYPEPTIDES AND COMPOSITIONS AND METHODS THEREOF
WO2023034991A1 (en) * 2021-09-02 2023-03-09 Kansas State University Research Foundation Mrna vaccine formulations and methods of using the same
WO2023039540A2 (en) * 2021-09-10 2023-03-16 Jacobs Technion-Cornell Institute Compositions and methods for determining humoral immune responses against seasonal coronaviruses and predicting efficiency of sars-cov-2 spike targeting, covid-19 disease severity, and providing interventions
KR102621026B1 (ko) * 2021-10-15 2024-01-09 에스케이바이오사이언스(주) 단백질의 정제방법
KR102527221B1 (ko) * 2021-10-15 2023-05-02 에스케이바이오사이언스 주식회사 단백질의 정제방법
KR102524839B1 (ko) * 2021-11-04 2023-04-25 에스케이바이오사이언스(주) 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
US20250000968A1 (en) * 2021-11-12 2025-01-02 The United States of America, as represented by the Secretary,Department of Health and Human Service Sars-cov-2 spike fused to a hepatitis b surface antigen
WO2023122257A2 (en) * 2021-12-22 2023-06-29 La Jolla Institute For Immunology Coronavirus spike glycoprotein with improved expression and stability
CN114656571B (zh) * 2022-02-18 2024-07-16 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 一种四价SARS-CoV-2嵌合纳米颗粒疫苗及其制备方法与应用
US20240207389A1 (en) * 2022-04-27 2024-06-27 Northwestern University Methods for improving covid vaccine immunogenicity
KR102689037B1 (ko) * 2022-07-12 2024-07-30 에스케이바이오사이언스 주식회사 SARS-CoV-2 백신 부스터 조성물
KR20250084945A (ko) * 2022-10-05 2025-06-11 유니버시티 오브 워싱턴 범사르베코바이러스 나노입자 백신
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016639A2 (en) * 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
US10248758B2 (en) * 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
WO2015080973A1 (en) * 2013-11-26 2015-06-04 Baylor College Of Medicine A novel sars immunogenic composition
US9630994B2 (en) * 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
WO2017046801A1 (en) * 2015-09-17 2017-03-23 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines
WO2018175560A1 (en) * 2017-03-22 2018-09-27 The Scripps Research Institute Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain
EP3606942B1 (en) * 2017-04-04 2025-06-11 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN112088014B (zh) * 2018-02-28 2026-03-24 华盛顿大学 自组装纳米结构疫苗

Also Published As

Publication number Publication date
EP4103230A1 (en) 2022-12-21
PE20230301A1 (es) 2023-02-13
WO2021163438A1 (en) 2021-08-19
MX2022009860A (es) 2022-11-07
CO2022011467A2 (es) 2022-10-31
KR20220142472A (ko) 2022-10-21
BR112022016220A2 (pt) 2022-10-25
JP2023513720A (ja) 2023-04-03
JP7897796B2 (ja) 2026-07-30
PH12022552099A1 (en) 2024-01-29
CN116096404A (zh) 2023-05-09
US20240277831A1 (en) 2024-08-22
AU2021221139A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
US20240277831A1 (en) Polypeptides, compositions, and their use to treat or limit development of an infection
Walls et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2
AU2022202787B2 (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use
Wu et al. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab
CN111995678A (zh) 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用
AU2014212268B2 (en) Respiratory Syncytial Virus F protein epitopes
US20240376180A1 (en) Human recombinant monoclonal antibody against sars-cov-2 spike glycoprotein
JP7329530B2 (ja) ノイラミニダーゼを含む広範に防御的なワクチン組成物を生成する方法
CN113173977B (zh) 一种双功能抗原、其制备方法及应用
CN103665152B (zh) 犬细小病毒单域抗体及其制备方法和应用
JP2023526274A (ja) Sars-cov2中和単一ドメイン抗体構築物
Ballegeer et al. A neutralizing single-domain antibody that targets the trimer interface of the human metapneumovirus fusion protein
WO2022271863A1 (en) Coronavirus neutralizing compositions and associated methods
CN102397559A (zh) 广谱型流感疫苗及其制备方法
US11242379B2 (en) Monoclonal antibodies and cocktails for treatment of Ebola infections
EP4248993A1 (en) New mers-cov vaccine
WO2016005545A1 (en) Substances and methods for the use in prevention and/or treatment in huntington's disease
US20220332759A1 (en) Targeted pulmonary delivery compositions and methods using same
WO2022106205A1 (en) Corona virus spike protein binding compounds
Amanat In depth characterization of immune response against the spike protein of Sars-CoV-2 in response to infection and mRna vaccination
HK40094028A (en) Polypeptides, compositions, and their use to treat or limit development of an infection
WO2026073202A1 (en) Sars-cov-2 receptor binding domain nanoparticles and methods of use thereof
KR20190129932A (ko) 폐렴구균 감염의 치료 및 예방을 위한 항-폐렴구균 과다면역 글로불린
WO2025024431A1 (en) Broadly reactive antibodies to influenza b viruses
CN120289641A (zh) 一种靶向fap的鲨鱼单域抗体4a1及其应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220916

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250127

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250127

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250127

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250403

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250801

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250805

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250911

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250911

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260122

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260122

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-P145 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - DEFECT(S)

Effective date: 20260423

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260505